Reuters logo
BRIEF-Acorda Resubmits New Drug Application For INBRIJA
December 7, 2017 / 11:13 AM / in 6 days

BRIEF-Acorda Resubmits New Drug Application For INBRIJA

Dec 7 (Reuters) - Acorda Therapeutics Inc:

* ACORDA RESUBMITS NEW DRUG APPLICATION FOR INBRIJA™ (CVT-301, LEVODOPA INHALATION POWDER)

* SAYS RESUBMISSION ADDRESSED TWO ISSUES RAISED IN RECENT REFUSAL TO FILE (RTF) LETTER

* SAYS RESUBMISSION ALSO INCLUDED ALL ADDITIONAL INFORMATION REQUESTED BY FDA IN ITS LETTER

* SAYS INBRIJA NDA IS BEING SUBMITTED AS A 505(B)(2) APPLICATION Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below